A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Clinical trial NCT06780137 · RECRUITING
Trial details
- NCT number
- NCT06780137
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-27
- Primary completion
- 2029-04-27
- Enrollment
- 327
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.